Immunotherapy hub study for liver tumor patients
Part of Cancer, Digestive system clinical trials.
This trial is checking how the immune system works in people with primary liver cancer, looking at ways to prevent infections and manage the tumor. It is an observational study—meaning no new treatments are given—so it helps doctors learn more without adding extra medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a primary liver tumor (a cancer that started in your liver).
- You cannot currently have any other type of cancer (except certain low-risk ones removed by surgery more than 3 years ago).
- You cannot have an active autoimmune disease that needs immune-suppressing medication.
- You cannot have HIV, active hepatitis B or C, or diabetes.
- You cannot have previously taken certain cancer drugs (like atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors, or anti-VEGF therapies).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
This study looks at how well immunotherapy combinations work as the first treatment for advanced liver cancer that can't be surgically removed. It will track real-world patients to see how safe and effective these treatments are.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
Hear when a new SARS CoV-2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.